Wells Fargo’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-7,985
Closed -$7K 7369
2019
Q4
$7K Sell
7,985
-100,143
-93% -$76.9K ﹤0.01% 5994
2019
Q3
$61K Sell
108,128
-242
-0.2% -$130 ﹤0.01% 5504
2019
Q2
$56K Sell
108,370
-50,400
-32% -$25.2K ﹤0.01% 5512
2019
Q1
$72K Buy
158,770
+1,993
+1% +$930 ﹤0.01% 5239
2018
Q4
$75K Sell
156,777
-3,538
-2% -$1.76K ﹤0.01% 5408
2018
Q3
$85K Buy
160,315
+995
+0.6% +$533 ﹤0.01% 5420
2018
Q2
$79K Sell
159,320
-414
-0.3% -$193 ﹤0.01% 5468
2018
Q1
$67K Buy
159,734
+565
+0.4% +$227 ﹤0.01% 5468
2017
Q4
$60K Sell
159,169
-20
-0% -$8 ﹤0.01% 5496
2017
Q3
$57K Sell
159,189
-235
-0.1% -$87 ﹤0.01% 5424
2017
Q2
$61K Buy
159,424
+1,563
+1% +$638 ﹤0.01% 5342
2017
Q1
$71K Buy
157,861
+99,855
+172% +$43.9K ﹤0.01% 5339
2016
Q4
$22K Sell
58,006
-1,295
-2% -$438 ﹤0.01% 5610
2016
Q3
$16K Sell
59,301
-1,683
-3% -$426 ﹤0.01% 5670
2016
Q2
$14K Sell
60,984
-1,417
-2% -$244 ﹤0.01% 5597
2016
Q1
$7K Buy
62,401
+554
+0.9% +$60 ﹤0.01% 5820
2015
Q4
$7K Sell
61,847
-13,098
-17% -$1.85K ﹤0.01% 5834
2015
Q3
$14K Sell
74,945
-14,975
-17% -$5.09K ﹤0.01% 5647
2015
Q2
$63K Sell
89,920
-1,283
-1% -$888 ﹤0.01% 5255
2015
Q1
$62K Sell
91,203
-122
-0.1% -$85 ﹤0.01% 4931
2014
Q4
$72K Sell
91,325
-2,518
-3% -$1.72K ﹤0.01% 4883
2014
Q3
$44K Buy
93,843
+26
+0% +$13 ﹤0.01% 4987
2014
Q2
$47K Sell
93,817
-1,017
-1% -$492 ﹤0.01% 4997
2014
Q1
$29K Sell
94,834
-3,882
-4% -$1.44K ﹤0.01% 5122
2013
Q4
$34K Buy
98,716
+27,262
+38% +$32.9K ﹤0.01% 4864
2013
Q3
$144K Sell
71,454
-76
-0.1% -$145 ﹤0.01% 4343
2013
Q2
$136K Buy
+71,530
New +$126K ﹤0.01% 4294

Wells Fargo's GCVRZ Position: Q1 2020 in Review

Wells Fargo sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2020, closing a stake of 7,985 shares — an estimated $7K sold.

Wells Fargo first reported a position in GCVRZ in Q2 2013 and held it in 27 quarters. The position peaked at $144K in Q3 2013. 2 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2020.

  • Wells Fargo reported no remaining Sanofi Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
  • Wells Fargo sold 7,985 Sanofi Contingent Value Rights shares in Q1 2020, an estimated $7K.
  • Wells Fargo first reported a position in Sanofi Contingent Value Rights in Q2 2013 and held it in 27 quarters.
  • Wells Fargo's Sanofi Contingent Value Rights position peaked at $144K in Q3 2013.
  • 2 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2020.

Based on Wells Fargo's 13F filing for Q1 2020, filed 14 May 2020.